On-Demand CME Videos
Plaque Psoriasis: Itching for New Topical Options: Online CME Activity
This activity was recorded at the 2022 Fall Clinical Dermatology Conference on October 22, 2022.
Plaque Psoriasis: Itching for New Topical Options
This activity is supported by an educational grant from Arcutis.
In order to ensure educational material is relevant, educational materials will expire after a certain time period. This course will be available for the following dates:
November 15, 2022
November 15, 2024
At the completion of this activity, participants should be better able to:
Overview of key data for emerging topical therapies to manage plaque psoriasis
Describe how to individualize care with emerging topical therapies to optimize patient outcomes
Compare between the various topical therapies for the management of plaque psoriasis
April Armstrong, MD, MPH
Chief, Division of Dermatology
David Geffen School of Medicine at UCLA
Los Angeles, CA
Neal Bhatia, MD
Director of Clinical Dermatology
Therapeutics Clinical Research
San Diego, CA
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of University of Nevada and CMEsquared. The University of Nevada is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation Statement
The University of Nevada designates this enduring activity for a maximum of 0.50 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosures & Disclaimers
Disclosures are as follows:
Grant/Research Support: BMS, Leo, UCB, Lilly, Dermavant, Dermira, Pfizer, AbbVie, ASLAN, BI, EPI, Incyte, Janssen
Consultant: Lilly, Novartis, Ortho, SUN, Dermavant, Dermira, Sanofi Regeneron, Pfizer, Parexel
Advisory Board/Consultant: Almirall, Biofrontera, Ferndale, Galderma, ISDIN, J & J, La Roche-Posay, Ortho, and SUN
Grant/Research Support: Almirall, Biofrontera, Ferndale, Galderma, ISDIN, J & J, La Roche-Posay, Ortho, and SUN
Speaker's Bureau: Almirall, Biofrontera, Ferndale, Galderma, ISDIN, J & J, La Roche-Posay, Ortho, and SUN
The University of Nevada discloses that all relevant conflicts have been satisfactorily mitigated.